Corvus Pharmaceuticals Inc. (C17)
XDUS
Real-time Data
06:00 AM
Day's Range
9.1552 wk Range
5.44Overview - C17 - Corvus Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
-3.63M
P/E (Trailing)
‪-56.44‬
PEG Ratio
‪-0.62‬
Price / Book
‪4.39‬
EV / EBITDA
‪0.05‬
Profitability
Return on Assets
‪-21.48%‬
Return on Equity
‪-24.97%‬
Ownership
Shares Outstanding
84.12M
Price stats
50-Day Avg
‪11.94‬
200-Day Avg
‪11.99‬
Peers - C17 - Corvus Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- C17XDUSCorvus Pharmaceuticals Inc.+49.28%52-week change-56.45P/E (Trailing)—Profit Margin
- 0QFXDUSModerna Inc.+85.69%52-week change—P/E (Trailing)—Profit Margin
- 0MEXDUSTwist Bioscience Corporation+84.27%52-week change-112.23P/E (Trailing)‪50.72%‬Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+82.13%52-week change-37.88P/E (Trailing)—Profit Margin
- 2LBXDUSIovance Biotherapeutics Inc.+80.83%52-week change-8.43P/E (Trailing)‪34.27%‬Profit Margin
- 42ZXDUSRevolution Medicines, Inc.+78.13%52-week change-30.44P/E (Trailing)—Profit Margin
- 3O8XDUSOmeros Corp.+77.85%52-week change-333.00P/E (Trailing)—Profit Margin
Profile Summary - C17 - Corvus Pharmaceuticals Inc.
About
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
